BACKGROUND AND AIMS: Alterations in gluconeogenesis in the diseased liver can be assessed non-invasively using magnetic resonance spectroscopy by measuring changes in phosphomonoester resonance which contains information regarding several metabolites, including the phosphorylated intermediates of the gluconeogenic pathway. METHODS: 31P magnetic resonance spectroscopy was used to determine changes in phosphomonoesters following bolus infusions of 2.8 mmol/kg L-alanine in five patients with functionally compensated cirrhosis and in five patients with functionally decompensated cirrhosis. RESULTS: Compared with six healthy volunteers, baseline phosphomonoester values were elevated by 35% (p<0.05) in the compensated cirrhosis group and by 57% (p<0.01) in the decompensated cirrhosis group. Following alanine infusion, phosphomonoesters in healthy volunteers increased by 46% from baseline values (p<0.01), in patients with compensated cirrhosis by 27% (p<0.02) but those with decompensated cirrhosis showed no increase from baseline. There was a reduction in the percentage of inorganic phosphate signal in all subjects. CONCLUSIONS: By analysing changes in phosphomonoester and inorganic phosphate resonances it is possible to discern clear metabolic differences between healthy volunteers and patients with cirrhosis of varying severity using magnetic resonance spectroscopy. Those patients with functionally decompensated cirrhosis have higher percentage baseline phosphomonoester values but the absence of phosphomonoester elevation following L-alanine infusion suggests that they are unable to mount a significant metabolic response with a progluconeogenic stimulus.
BACKGROUND AND AIMS: Alterations in gluconeogenesis in the diseased liver can be assessed non-invasively using magnetic resonance spectroscopy by measuring changes in phosphomonoester resonance which contains information regarding several metabolites, including the phosphorylated intermediates of the gluconeogenic pathway. METHODS: 31P magnetic resonance spectroscopy was used to determine changes in phosphomonoesters following bolus infusions of 2.8 mmol/kg L-alanine in five patients with functionally compensated cirrhosis and in five patients with functionally decompensated cirrhosis. RESULTS: Compared with six healthy volunteers, baseline phosphomonoester values were elevated by 35% (p<0.05) in the compensated cirrhosis group and by 57% (p<0.01) in the decompensated cirrhosis group. Following alanine infusion, phosphomonoesters in healthy volunteers increased by 46% from baseline values (p<0.01), in patients with compensated cirrhosis by 27% (p<0.02) but those with decompensated cirrhosis showed no increase from baseline. There was a reduction in the percentage of inorganic phosphate signal in all subjects. CONCLUSIONS: By analysing changes in phosphomonoester and inorganic phosphate resonances it is possible to discern clear metabolic differences between healthy volunteers and patients with cirrhosis of varying severity using magnetic resonance spectroscopy. Those patients with functionally decompensated cirrhosis have higher percentage baseline phosphomonoester values but the absence of phosphomonoester elevation following L-alanine infusion suggests that they are unable to mount a significant metabolic response with a progluconeogenic stimulus.
Authors: P C Dagnelie; D K Menon; I J Cox; J D Bell; J Sargentoni; G A Coutts; J Urenjak; R A Iles Journal: Clin Sci (Lond) Date: 1992-08 Impact factor: 6.124
Authors: T Schricker; G Albuszies; H Weidenbach; K Beckh; H Ensinger; T Anhäupl; P Radermacher; J Vogt; G Adler; M Georgieff Journal: Hepatology Date: 1996-08 Impact factor: 17.425
Authors: M Merli; F Leonetti; O Riggio; V Valeriano; M C Ribaudo; F Strati; G Tisone; C U Casciani; L Capocaccia; F Sprati Journal: Hepatology Date: 1999-09 Impact factor: 17.425
Authors: I J Cox; D K Menon; J Sargentoni; D J Bryant; A G Collins; G A Coutts; R A Iles; J D Bell; I S Benjamin; S Gilbey Journal: J Hepatol Date: 1992-03 Impact factor: 25.083
Authors: D K Menon; J Sargentoni; S D Taylor-Robinson; J D Bell; I J Cox; D J Bryant; G A Coutts; K Rolles; A K Burroughs; M Y Morgan Journal: Hepatology Date: 1995-02 Impact factor: 17.425
Authors: S D Taylor-Robinson; J Sargentoni; J D Bell; N Saeed; K K Changani; B R Davidson; K Rolles; A K Burroughs; H J Hodgson; C S Foster; I J Cox Journal: Liver Date: 1997-08
Authors: Irene Marco-Rius; Cornelius von Morze; Renuka Sriram; Peng Cao; Gene-Yuan Chang; Eugene Milshteyn; Robert A Bok; Michael A Ohliger; David Pearce; John Kurhanewicz; Peder E Z Larson; Daniel B Vigneron; Matthew Merritt Journal: Magn Reson Med Date: 2016-11-17 Impact factor: 4.668
Authors: Christopher Scott; Rebecca Stokes; Kuan Minn Cha; Andrew Clouston; Mohammed Eslam; Mayda Metwally; Michael M Swarbrick; Jacob George; Jenny E Gunton Journal: PLoS One Date: 2019-12-04 Impact factor: 3.240
Authors: Steven F Solga; Alena Horska; Susanne Hemker; Stephen Crawford; Charalett Diggs; Anna Mae Diehl; Frederick L Brancati; Jeanne M Clark Journal: Liver Int Date: 2008-03-04 Impact factor: 5.828